By Doug Macron
The European Patent Office agreed late last month to consider restarting its review of a patent application covering Mirrx Therapeutics' core microRNA antagonist technology roughly six months after it said that it would not do so until litigation surrounding the intellectual property had been decided.
According to an EPO filing, the organization will hear Mirrx's argument for resuming patent proceedings on July 11.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.